Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: Insights from the ARISTOTLE trial

European Heart Journal

Volumn 35, Issue 4, 2014, Pages 224-232

  Alexander, John H ^a   Lopes, Renato D ^a   Thomas, Laine ^a   Alings, Marco ^b   Atar, Dan ^c   Aylward, Philip ^d   Goto, Shinya ^e   Hanna, Michael ^f   Huber, Kurt ^g   Husted, Steen ^h   Lewis, Basil S ⁱ   McMurray, John J V ^j   Pais, Prem ^k   Pouleur, Hubert ^l   Steg, Philippe Gabriel ^m   Verheugt, Freek W A ⁿ   Wojdyla, Daniel M ^a   Granger, Christopher B ^a   Wallentin, Lars ^o  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Working Group on Cardiovascular Research the Netherlands   (Netherlands)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e TOKAI UNIVERSITY   (Japan)

^f BRISTOL MYERS SQUIBB   (United States)

^g WILHELMINEN HOSPITAL   (Austria)

^h AARHUS UNIVERSITY   (Denmark)

ⁱ CARMEL MEDICAL CENTER   (Israel)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^l PFIZER INC   (United States)

^m BICHAT HOSPITAL   (France)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^o UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

Aspirin; Atrial fibrillation; Concomitant medications; Major bleeding; Stroke; Systemic embolism

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; WARFARIN;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASCULAR DISEASE;

ASPIRIN; ATRIAL FIBRILLATION; CONCOMITANT MEDICATIONS; MAJOR BLEEDING; STROKE; SYSTEMIC EMBOLISM;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EMBOLISM; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84890427300     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht445     Document Type: Article

References (29)

1. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
2. American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:e269-e367.
3. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-Analysis. Ann Intern Med 1999;131: 492-501.
4. Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867.
5. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, FranzosiMG, Healey JS, Yusuf S. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029-2037.
6. ACTIVE Writing Group of theACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006;367:1903-1912.
7. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120:2271-2306.
8. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP. 2012 ACCF/AHA focused update on the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:645-681.
9. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR.Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-Analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-250.
10. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-Analysis of 25, 307 patients. Eur Heart J 2006;27:519-526.
11. Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen MA, Airaksinen TJ, Niemela M, Vahlberg T, Airaksinen KE. Safety and efficacy of combined antiplateletwarfarin therapy after coronary stenting. Eur Heart J 2007;28:726-732.
12. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrøm SZ, Poulsen HE, Køber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433-1441.
13. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H.Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-974.
14. van Es RF, Jonker JJ, VerheugtFW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): A randomized controlled trial. Lancet 2002;360:109-113.
15. Dentali F, Douketis JD, LimW, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: A meta-Analysis of randomized trials. Arch Intern Med 2007;167:117-124.
16. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, VerheugtFW, Gibson CM.Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
17. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365: 699-708.
18. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting.ANorth-American perspective. Thromb Haemost 2011;106:572-584.
19. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marín F. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010;103:13-28.
20. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, GoAS, Hughes M, Spenser F, Manning WJ, Halperin JL, Lip GYH. Antithrombotic therapy for atrial fibrillation, antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012;141:e531S-75S.
21. Granger CB, Alexander JH, McMurray JV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981-992.
22. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale. Am Heart J 2010;159: 331-339.
23. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
24. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012;59: 1413-1425.
25. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Ergou S, Sattar N, Ray KK. Effect of aspirin on nonvascular outcomes: Meta-Analysis of randomized controlled trial. Arch Intern Med 2012;172:209-216.
26. Rembold CM. Aspirin does not reduce CHD or cancer mortality but increases bleeding. Ann Intern Med 2012;156:JC6-3.
27. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004;364: 331-337.
28. FlakerGC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, HalinenMO, Horrow J, Halperin JL. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006;152:967-973.
29. Antithrombotic Trialists' Collaboration. Collaborative meta-Analysis of randmized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.